Humana (NYSE:HUM) Lowered to Market Perform at Leerink Partners

by · The Cerbat Gem

Leerink Partners cut shares of Humana (NYSE:HUM – Free Report) from an outperform rating to a market perform rating in a research note released on Wednesday morning, Marketbeat reports. The brokerage currently has $250.00 target price on the insurance provider’s stock, down from their previous target price of $400.00.

Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald reissued a neutral rating and issued a $395.00 price target on shares of Humana in a report on Tuesday, October 1st. TD Cowen raised their price target on Humana from $396.00 to $407.00 and gave the company a buy rating in a research report on Wednesday, July 24th. Truist Financial upped their price objective on Humana from $355.00 to $400.00 and gave the stock a hold rating in a report on Monday, July 15th. Piper Sandler initiated coverage on Humana in a report on Wednesday, June 26th. They set an overweight rating and a $392.00 price objective on the stock. Finally, Oppenheimer boosted their target price on Humana from $370.00 to $400.00 and gave the stock an outperform rating in a research report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, sixteen have given a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Hold and an average target price of $357.24.

Check Out Our Latest Research Report on Humana

Humana Price Performance

NYSE:HUM opened at $240.03 on Wednesday. Humana has a 52-week low of $213.31 and a 52-week high of $530.54. The stock has a fifty day moving average of $337.70 and a 200 day moving average of $342.66. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66. The firm has a market capitalization of $28.92 billion, a price-to-earnings ratio of 14.95, a P/E/G ratio of 2.44 and a beta of 0.50.

Humana (NYSE:HUM – Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. The firm had revenue of $29.54 billion during the quarter, compared to the consensus estimate of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter last year, the company posted $8.94 EPS. On average, research analysts expect that Humana will post 16.01 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be paid a $0.885 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.47%. Humana’s dividend payout ratio (DPR) is currently 22.04%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of HUM. Mendota Financial Group LLC lifted its position in shares of Humana by 9.2% during the 2nd quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock valued at $119,000 after buying an additional 27 shares in the last quarter. Aurora Investment Counsel boosted its stake in Humana by 1.3% during the fourth quarter. Aurora Investment Counsel now owns 2,273 shares of the insurance provider’s stock valued at $1,155,000 after buying an additional 29 shares during the last quarter. Capital Advisors Ltd. LLC increased its stake in Humana by 17.0% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock worth $80,000 after acquiring an additional 31 shares during the last quarter. EP Wealth Advisors LLC boosted its position in shares of Humana by 1.6% during the 4th quarter. EP Wealth Advisors LLC now owns 2,294 shares of the insurance provider’s stock valued at $1,050,000 after acquiring an additional 37 shares during the last quarter. Finally, CarsonAllaria Wealth Management Ltd. lifted its position in Humana by 111.4% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after purchasing an additional 39 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Humana

(Get Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Stories